financetom
Business
financetom
/
Business
/
US pension fund CalPERS backs Peltz, Rasulo in Disney board battle
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US pension fund CalPERS backs Peltz, Rasulo in Disney board battle
Mar 29, 2024 5:44 PM

NEW YORK (Reuters) -The California Public Employees Retirement System (CalPERS) said on Friday it voted to elect activist investment firm Trian Fund Management's two director candidates to Walt Disney's board, in one of the most closely watched and expensive battles for corporate control.

"CalPERS believes Walt Disney Co will benefit from fresh eyes on its board of directors and voted its company shares in favor of candidates Nelson Peltz and Jay Rasulo," the U.S. pension fund, which owned 6.65 million shares in the entertainment giant at the end of December, told Reuters.

CalPERS, which ranks among Walt Disney's top 30 investors, according to LSEG data, said its "established voting guidelines focus on the need for independent corporate boards, a say in setting executive pay, and increased transparency. Two new directors who are qualified and capable of leading needed change in corporate governance will serve the Disney board well."

Shareholders will decide at next week's annual meeting who will sit on the home of Mickey Mouse's 12-person board and help guide strategy as CEO Bob Iger seeks to transform a company valued at $224 billion.

As more big shareholders are expected to cast votes in the coming days, Disney is racing to convince investors there is no need for new blood on the board at a time when the share price has climbed and Iger has laid out new initiatives to cut costs and reignite the company's creative spark.

Trian and another hedge fund, Blackwells Capital, which is trying to win three Disney board seats, are doing the same, telling investors the Disney board has bungled succession planning for Iger, needs to better harness technology, and should consider separating its real estate holdings.

Proxy advisory firm Institutional Shareholder Services (ISS) recommended that investors elect Peltz, while its much smaller rival, Egan-Jones, recommended votes for Peltz and Rasulo, a former Disney chief financial officer who was passed over for the top job at the entertainment company years ago. Glass Lewis, another proxy advisory firm, suggested investors back all of Disney's 12 directors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Market Chatter: Eli Lilly Selling Bonds to Fund $2.5 Billion Cancer Drug Purchase
Update: Market Chatter: Eli Lilly Selling Bonds to Fund $2.5 Billion Cancer Drug Purchase
Feb 11, 2025
09:49 AM EST, 02/11/2025 (MT Newswires) -- (Updates with refusal to comment from Eli Lilly ( LLY ) in the fourth paragraph.) Eli Lilly ( LLY ) is selling bonds to help fund its planned $2.5 billion purchase of a cancer drug from Scorpion Therapeutics, Bloomberg News reported Monday, citing a source with knowledge of the matter. The company plans...
Ford CEO decries
Ford CEO decries "cost and chaos" of Trump tariffs
Feb 11, 2025
DETROIT, Feb 11 (Reuters) - Ford Motor ( F ) CEO Jim Farley said U.S. President Donald Trump's proposed and implemented tariffs have added a lot of cost and a lot of chaos, although Farley said he believes the president aims to strengthen the American auto industry overall. The automaker is considering areas in which it can build up inventory...
Patterson-UTI Energy Reports Average US Drilling Rig Count for January
Patterson-UTI Energy Reports Average US Drilling Rig Count for January
Feb 11, 2025
09:45 AM EST, 02/11/2025 (MT Newswires) -- Patterson-UTI Energy ( PTEN ) said Tuesday that it had an average of 106 drilling rigs operating in the US in January. Shares of the company were up 1.5% in recent Tuesday trading. Price: 9.09, Change: +0.11, Percent Change: +1.22 ...
BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis
BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis
Feb 11, 2025
09:46 AM EST, 02/11/2025 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Tuesday that the European Commission has granted marketing authorization for acoramidis, under the brand name Beyonttra, to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy. BridgeBio said German pharmaceutical company Bayer will launch acoramidis in H1 of 2025 in the European Union. BridgeBio also said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved